Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
- The German series proving subtitles can be sexy — and wildly addictive
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- Pick Your Top Method for starting the Morning
- New movies to watch this weekend: See 'The Running Man' in theaters, rent 'One Battle After Another,' stream 'Nobody 2' on Peacock
- Finding the Force of Mentorship: Self-awareness Through Direction
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
